Experiences with

Idelalisib

I am currently on the Bruin-321 trial and am on my 3rd cycle of Pirtobrutinib, after a very rough time with Idelalisib + Rituximab infusions. They are not financially able to stay in hotels etc. and no other relatives close by. I don't know what I am feeling.

I am in a clinical trial and am currently taking Idelalisib. The rest of my blood work is good. Jack

acalabrutinib - duvelisib - ibrutinib - idelalisib - pirtobrutinib - zanabrutinib rituximab - obinutuzumab - venetoclax - Learn More Managing Common Side Effects Chemoimmunotherapy Drug Types and Classes Clinical Trials

I am on the Bruin trial and was randomized to Arm B which is Idelalisib and Rituximab ( 6 months of infusions ). My bloodwork so far has shown slight improvement since the start in January of this year.

Moreso, the adverse events associated with idelalisib or duvelisib can be significant, especially with regard to grade 3 diarrhea or colitis.

well aware of this[i] "vacuum beyond BTKi and BCL-2 inhibition"[/i] and research is continuing into how modified use of PI3Ki drugs, such as intermittent dosing, can again gain the approval of the FDA for the use of later generation PI3Ki drugs such as duvelisib, umbralisib and zandelisib, now that idelalisib

Has anybody got experience with idelalisib. Many thanks ☺️

However, the severe toxicity profile associated with the first-generation inhibitors idelalisib and duvelisib, combined with the availability of other more tolerable agents, have limited their use."

Hi all, I was diagnosed in 2015 with CLL with 17p del & started Idelalisib at the Christie which got it under control for a few years until it failed. I was then put on Venetoclax which amazingly got me into remission but it has now started to fail.

Brian Koffman gives up updates on the reversible non-covalently binding BTKi (Bruton’s tyrosine kinase inhibitor) pirtobrutinib (formerly LOXO-305), another reversable BTKi known as MK-1026 (formerly ARQ-531), 3-year follow-up data from the Ascend Trial: Acalabrutinib vs Rituximab plus Idelalisib

this is why you are seeing ads for Leukemia drugs on tv .. this is from wikipedia ----"According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.[16]: 3, 7–8  Competition as well as potential for combination is expected from other drugs such as ibrutinib and idelalisib

Is that the right approach or should she switch to Venetoclax or Idelalisib/Duvelisib? Any insight you have is very helpful. Thank you

. - PI3K Inhibitors for CLL March 7th 2022 https://www.onclive.com/view/pi3k-inhibitors-for-cll A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia. - Noncovalent BTK Inhibitors in CLL March 7th 2022 https://www.onclive.com/view/noncovalent-btk-inhibitors-in-cll

However, when patients relapse or become refractory to these, the approved PI3Kinase inhibitors duvelisib or idelalisib, and the still-experimental umbralisib offer potent and potentially helpful third options. Side effects of PI3ks have made some patients apprehensive.

A update on my very surprising results when combining Ibrutinib + Idelalisib + Venetoclax. Initial Post with more detail: https://healthunlocked.com/cllsupport/posts/145327977/my-n-of-1-trial-with-ibrutinib-idelalisib-venetoclax-that-lead-to-remission-of-richters-in-three-weeks.

I started with 2x150mg Idelalisib + 280mg Ibrutinib + 200mg Venetoclax. This is now lowered to 2x150mg Idelalisib, 140mg Ibrutinib, 100mg Venteoclax pr day, the bone marrow is still suppressed on this combination and it would not be a good treatment long term.

I started with 2x150mg Idelalisib + 280mg Ibrutinib + 200mg Venetoclax. This is now lowered to 2x150mg Idelalisib, 140mg Ibrutinib, 100mg Venteoclax pr day, the bone marrow is still suppressed on this combination and it would not be a good treatment long term.

No common resistance-associated mutations or deregulated signaling pathways have been reported in idelalisib failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax. For 20% of patients, the ibrutinib resistance-associated mutations remain unknown.

* What about Idelalisib, which I’ve read is well tolerated? * If I were to discontinue Imbruvica, which other drug would you recommend? Whichever it might be, I’d like to start at a lower dose than typically recommended. * What do you think of CBD oil for my agitation?

Take home message is that Acalabrutinib significantly improved PFS and that Plus Rituximab treatment was associated with a high level of serious adverse events compared to the other treatments.